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rates of IGF-II P3 in the adjacent tissues in poorly differentiated
HCC were lower than well-differentiated ones (P=0.000); At the
same time, the methylation rates of IGF-II P3 in HBsAg-positive
HCC was signiﬁcantly lower than those with HBsAg-negative
(P=0.026).
Conclusions: The methylation status of IGF-II promoter is closely
related to the malignant transformation of hepatocytes at the
early stage of HCC, and helpful to explore the pathogenesis of
HCC.
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Objective: To investigate the effect of blocking the expression
of hALR with small interfering RNA (siRNA) targeting ALR on the
expression of TGF-α and EGFR of HCC cell line HepG2.
Methods: The expressing siRNA plasmid pSIALR-A targeting hALR
and the unrelated control plasmid pSIALR-B were transfected
into HepG2 cells with lipofectamine 2000 methods, respec-
tively. The expression of green ﬂuorescent protein was observed
under a ﬂuorescent microscope to calculate transfection efﬁ-
ciency. The protein level of hALR in the transfected cells was
measured by immunocytochemistry to determine the inhibitory
effect. According to different plasmid transfection, HepG2 cells
were divided into three groups: transfection group (transfected
pSIALR-A), the control group (transfected pSIALR-B), blank con-
trol group (non-transfected with the recombinant plasmid). The
expression of TGF-α in the cell culture supernatant was detected
by radioimmunoassay, the expression of EGFR was detected by
Western blot.
Results: In transfection group, blank group and the unre-
lated control group, expression of TGF-α is (5.27±0.86) pg/ml,
(7.92±2.65) pg/ml and (6.50±1.28) pg/ml, respectively,the dif-
ference of transfection group and blank group, transfection
group and the unrelated control group was statistically signiﬁ-
cant (P<0.05); the relative expression of EGFR is 0.946±0.136,
1.115±0.606 and 1.131±0.509, respectively,the difference of
transfection group and blank group, transfection group and the
unrelated control group was statistically signiﬁcant (P<0.05).
Conclusion: In the complex cytokine network which promotes
the growth of hepatomas, augmenter of liver regeneration played
an important role in the occurrence and development of hep-
atic carcinoma not only by stimulating hepatomas proliferation
directely but also by up-regulating the expression level of TGF-α
and EGFR.
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OL-060 Dose-dependent effects of antitubercular drug on
liver, lung and spleen contents of free amino
acids
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Valentina Kovalenko. SI Institute of Pharmacology and
Toxicology Academy of Medical Sciences of Ukraine
Introduction: Further optimization of tuberculosis chemotherapy
requires a comprehensive evaluation of the effects of antituber-
cular drugs on metabolic processes in liver and Mycobacterium
tuberculosis-targeted organs.
Materials and Methods: Wistar albino male rats (body weight
(bw), 160–200 g) were divided into three groups: group I re-
ceived pyrazinamide per os at a dose of 1000 mg/kg bw/day,
group II - a dose of 2000 mg/kg bw/day, in both group it was given
for 60 days; the control group was composed of intact animals.
The contents of free amino acids in the liver, lung and spleen
were determined using an amino acid analyzer ÀÀÀ-881 (Czech
Republic).
Results and Discussion: The study of the effects of pyrazinamide
on the liver, lung and spleen contents of free amino acids in
the rats showed the largest number of changes in the liver at
a dose 1000 mg/kg bw/day and in the lung and spleen - at a
dose 2000mg/kg bw/day. At a dose 2000mg/kg in the lung, the
content of free amino acids at the level of 18 amino acids and
total sum of amino acids signiﬁcantly differed from controls. In
the spleen, this difference was observed at the level of 14 amino
acids and total sum of amino acids.
Conclusions: The study of the inﬂuence of pyrazinamide on liver,
lung and spleen contents of free amino acids allows to fully esti-
mate the dose-dependent effects of this substance on metabolic
processes in these organs.
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Background: We constructed one candidate subunit vaccine
AMDB made up of a fusion protein Ag85B-Mpt64190-198-Mtb8.4
(AMM), and a compound adjuvant consisting of dimethyl-
dioctyldecyl ammonium bromide (DDA) and BCG polysaccharide
nucleic acid (BCG-PSN). The immunogenicity of this vaccine and
its capability to boost BCG primed immunity were investigated.
Method: To investigate the immunogenicity of the vaccine, mice
were immunized subcutaneously with the vaccine with a 2-week
interval between the immunizations. Furthermore, AMM in DDA
with or without BCG-PSN was used to boost BCG-primed immunity
once, twice and thrice 6-10 weeks after BCG injection with 2
weeks interval respectively in C57BL/6 mice. The immune reac-
tion, protective efﬁcacy and pathology were determined after
vaccine immunization.
Results: The subunit vaccine based on the fusion protein AMM
induced more effective humoral and cell-mediated immune re-
sponses than the one based on the single antigen Ag85B. Mice
immunized with BCG primed and boosted by AMM twice produced
a stronger immune response than the one immunized with BCG
alone or the one boosted by Ag85B and afforded signiﬁcant
protection against M. tuberculosis infection. Lung histopathol-
ogy examination indicated that the AMM vaccine containing DDA
and BCG-PSN as adjuvant could reduce the pathological lesion
compared with the AMM vaccine containing DDA alone.
Conclusion: Subunit vaccine AMDB induced a strong Th1-type
immune response. Based on BCG priming, AMDB vaccine boosting
twice could enhance the immunogenicity and protection against
M. tuberculosis in mice.
